0001520138-26-000154
SEC filingBioVie's Q3 FY2026 net loss widened to $5.3M as operating expenses increased, while cash burn accelerated and the company faces substantial doubt about its ability to continue as a going concern.
Net cash used in operating activities for the nine months ended March 31, 2026 was $14.9 million, compared to $13.4 million in the prior year period. The increase in cash burn reflects the Company's continued investment in its clinical pipeline. Management has expressed substantial doubt about the Company's ability to continue as a going concern, as BioVie has not generated any revenue and does not expect to in the foreseeable future. The Company expects to fund operations through sales of equity, obtaining loans, or other strategic transactions, but there is no assurance that such financing will be available on acceptable terms.
BioVie's primary value driver is the Sunrise PD Phase 2 study, which completed enrollment in January 2026. Topline results are expected in mid-2026 and represent a significant catalyst for the Company. The Phase 2 study for Long COVID is ongoing, with activities decreasing as the study progresses. The Company also continues to advance its pipeline in other indications, though no specific milestones were disclosed for the quarter.
The Company's financial position remains constrained, with no revenue and significant operating losses. The net loss per diluted share was $0.70 for the quarter, compared to $0.15 in the prior year quarter. The increase in loss per share reflects both the wider net loss and the impact of equity issuances. Management continues to evaluate financing options to support operations and advance its clinical programs.